News

Read the

Three BC Cancer clinical investigators are participating in the Canadian Cancer Trials Group (CCTG) VISION – Investigator Leadership Training Program, a new education and mentorship initiative focused on developing leadership skills among current and emerging clinical trialists.

Drs. Leah Lambert, Jonathan Loree and Lucia Nappi are part of the inaugural VISION cohort.

For patients undergoing breast radiotherapy to treat their cancer, receiving a high-quality standard of care is important – particularly given they receive treatment over several sessions. 

However, this consistency can be challenging to maintain as each patient’s body is different. Positioning the breast accurately is key to ensuring the radiation targets the right area, yet variations in body shape and size can make this difficult. 

Investigators from BC Cancer – Prince George (Centre for the North) are co-authors on three international collaborative publications featured in the same issue of The Lancet Oncology.

Researchers at BC Cancer Research Institute, led by Dr. Bernie Eigl, director of the Provincial Clinical Trials Office, and Dr. Alex Wyatt, senior scientist and scientific director of the Cancer Genetics and Genomics Laboratory, examined whether a blood test that analyzes cancer-derived DNA found in the blood, called circulating tumour DNA (ctDNA), could help identify more patients with metastatic urothelial carcinoma – an aggressive form of bladder cancer – who are eligible for FGFR-targeted therapy.

Three projects led by BC Cancer researchers and focused on advancing cancer care have been funded through the inaugural UBC AI and Health Network Fellows Program, which supports researchers harnessing artificial intelligence (AI) to transform health research and improve patient care across BC.